FDA Inspection 1058064 — Robert Gurlich
The FDA completed an inspection of Robert Gurlich on May 25, 2018 in Prague. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- May 25, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Prague (Czech Republic)
Additional Details
Clinical Investigator (CI)